MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) and Orion Corporation (“Orion”) announced that notice has been provided of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and other candidates targeting CYP11A1 into an exclusive global license for MSD. Read more.